脂蛋白的新疗法:心血管风险估计和治疗的最新情况
Anders Berg Wulff1,2,3, Børge G Nordestgaard1,2,3,4, Anne Langsted5,6,7
1Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
脂蛋白是心血管疾病的一个关键风险因素. 新药在临床试验中显示出有效降低脂蛋白水平和降低心血管风险的前景.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脂蛋白是心血管疾病 (CVD) 和死亡率的重要因果风险因素.
- 目前有效降低脂蛋白的治疗选择有限.
- 全球指导方针现在建议进行普遍的,一次性的脂蛋白查.
研究的目的:
- 审查最近关于脂蛋白作为心血管疾病风险因素和治疗点的发现.
- 讨论目前管理脂蛋白的临床建议.
- 总结一下新兴的脂蛋白降低药物.
主要方法:
- 审查流行病学和遗传学研究,确定脂蛋白的因果关系.
- 对新型治疗剂的临床试验数据的分析.
- 综合现行国际临床指南.
主要成果:
- 已确立的脂蛋白 (a) 作为心血管疾病的因果风险因素.
- 在1/2期试验中,通过新型疗法 (ASO,siRNA,口服抑制剂) 显著降低脂蛋白 (高达106%) 已被证明.
- 没有观察到与这些新疗法相关的重大不良影响.
结论:
- 脂蛋白 (a) 是一个有效的治疗点,用于降低心血管疾病风险.
- 新兴的药理干预措施在降低脂蛋白中显示出高的有效性和安全性.
- 目前正在进行的第三期试验预计将导致用于管理与脂蛋白相关的心血管风险的新疗法.
更多相关视频
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
